BioAge Labs (NASDAQ:BIOA) Trading Up 8.7% – What’s Next?

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) rose 8.7% during mid-day trading on Tuesday . The company traded as high as $16.85 and last traded at $17.20. Approximately 39,262 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 739,205 shares. The stock had previously closed at $15.83.

Analyst Upgrades and Downgrades

BIOA has been the topic of several recent research reports. Oppenheimer began coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 target price on the stock. Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a report on Wednesday, February 4th. Citigroup upped their price objective on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Piper Sandler assumed coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, Needham & Company LLC assumed coverage on BioAge Labs in a report on Friday. They issued a “buy” rating and a $50.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $46.25.

BioAge Labs Trading Up 12.4%

The firm’s 50 day moving average price is $19.80 and its 200-day moving average price is $13.15. The company has a market cap of $789.56 million, a P/E ratio of -8.01 and a beta of 1.21.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%. The business had revenue of $3.08 million for the quarter.

Insider Transactions at BioAge Labs

In related news, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares of the company’s stock, valued at $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the completion of the sale, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. This represents a 54.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 267,540 shares of company stock worth $4,895,168 in the last three months. Insiders own 20.82% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BIOA. CWM LLC grew its holdings in BioAge Labs by 39.9% during the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the period. Russell Investments Group Ltd. acquired a new stake in BioAge Labs in the third quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new position in shares of BioAge Labs during the fourth quarter worth $77,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of BioAge Labs during the second quarter worth $27,000. Finally, Nisa Investment Advisors LLC grew its holdings in shares of BioAge Labs by 4,219.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the period.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.